B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves’ Disease: A Controlled Pilot Study

Abstract

RTX treatment may induce sustained remission in patients with GD with low TRAb levels. However, RTX did not affect autoantibody levels and seems ineffective in patients with high TRAb levels. At present, high cost, low efficacy, and potential side effects do not support use in uncomplicated GD.

References

Page 1

	Year	Citations
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trial Paul Emery, Roy Fleischmann, Anna Filipowicz‐Sosnowska, Arthritis & Rheumatism	2006	1K
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis Maria Leandro, Geraldine Cambridge, Michael R. Ehrenstein, Arthritis & Rheumatism	2006	549
The Determination of Thyroid Volume by Ultrasound and Its Relationship to Body Weight, Age, and Sex in Normal Subjects László Hegedüs, Hans Perrild, Lars Rytter Poulsen, The Journal of Clinical Endocrinology & Metabolism	1983	365
Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression Mario Salvi, Guia Vannucchi, Irene Campi, European Journal of Endocrinology Ocular DiseaseAutoimmune DiseaseOphthalmologyIntraorbital B-cell DepletionThyroid Disease	2006	146
Serum Thyrotropin Receptor Antibodies Concentrations in Patients with Graves' Disease Before, at the End of Methimazole Treatment, and After Drug Withdrawal: Evidence That the Activity of Thyrotropin Receptor Antibody and/or Thyroid Response Modify During the Observation Period Carlo Carella, Gherardo Mazziotti, F. Sorvillo, Thyroid	2006	117
Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4<sup>+</sup> T cell proliferation in response to self antigens Claus Henrik Nielsen, László Hegedüs, Robert Graham Quinton Leslie European Journal of Immunology	2003	61
Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4+ T cells in healthy individuals Claus Henrik Nielsen, Robert Graham Quinton Leslie, Bettina S. Jepsen, European Journal of Immunology	2001	59
Tolerability and safety of rituximab (MabThera Eva Kimby Oncology in Clinical Practice MedicineAntygenu Cd20PharmacotherapyRituksymab Nie WplywaRozpoczecia Terapii	2006	39
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab J. Boye, T. Elter, A. Engert Annals of Oncology Lymphoid NeoplasiaAllergyAutoimmune DiseaseImmunologyCurrent Clinical Use	2003	18

Page 1